Will Ultragenyx announce the U.S. commercial launch of Genglycos by 31 October 2026?
Posted 2026-10-02 — 29 days before the deadline, stated before the outcome.
Ultragenyx Pharmaceutical is a biotechnology company focused on developing treatments for rare genetic diseases. Genglycos is a therapeutic agent developed by the company for the management of mucopolysaccharidosis type IV.
The claim
Ultragenyx will announce the U.S. commercial launch of Genglycos on or before 2026-10-31.
Reasoning trace
- FDA approval of Genglycos
- Ultragenyx activates its commercial infrastructure and treatment centers
- Ultragenyx announces Genglycos is available for prescription
Evidence so far
0 confirming · 0 denying signals · 0 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 3 times since mint (last on 2026-10-04) — 87% at mint → 75% today.
What to watch
- milestone Ultragenyx announces the activation of its commercial infrastructure or the opening of treatment centers for Genglycos
- leading indicator Ultragenyx reports in a public filing or statement that Genglycos is available for prescription in the U.S.
- leading indicator Ultragenyx issues a press release announcing the commercial availability of Genglycos in the United States
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.